msg life ag: msg life and IBM strengthen insurance digitization by leveraging leading End-To-End platform capabilities for the life insurance & pensions industry outside the German-speaking countries
(Leinfelden-Echterdingen/Ehningen, Germany): The msg.Insurance Suite Life is an innovative digital software platform that tracks the entire value chain of life insurance companies and pension providers. At the heart of the platform is the leading European policy administration solution msg.Life Factory. It offers insurers the concentrated know-how of more than 40 years’ experience in the industry, the security of msg life’s unique track record, combined with innovative, future-proof business solutions and state-of-the-art technologies. The innovative complete solution enables end-to-end digital processing of all core insurance processes across all components and sets industry-wide benchmarks for business value, efficiency and innovation.
Insurers using the msg.Insurance Suite Life can overcome market challenges, boost their competitiveness and sustainably reduce administrative expenses.
The joint value proposition from IBM and msg life features software solutions from msg life as well as technology platforms like the IBM Cloud. Now with the support from IBM, msg life will be infused with Artificial intelligence capabilities to increase efficiency of clients’ processes due to higher automation rates. IBM brings these competences together in its role as a digital transformation partner and end-to-end platform provider.
msg life contributes its product and licenses to this new partnership. Outside German-speaking Europe, IBM markets and implements the msg.Insurance Suite Life internationally with support from msg life and its strong industry expertise.
For Milenko Radic, Management Board member at msg life, the partnership is the result of a highly successful and trusting collaboration that both companies have shared for more than a decade. Radic continues: “The leading market position and strength of msg.Insurance Suite Life, combined with IBM’s global presence and innovative technologies and platforms, are crucial factors in the successful positioning of the solution as a leading platform for the global life and pension insurance industry. The basis is formed by the long-standing and trustworthy business relationship between the two companies and joint references in strategic transformation projects.”
“Insurance companies today need to find a way to manage life insurance policies that are no longer being sold on the market but still are administered by the insurer. These books of business can present challenges to insurers because the policies often reside in legacy systems that can be hampered by siloed, inflexible and expensive-to-maintain technology,” said Thomas Rechnitzer, Insurance Industry Leader EMEA at IBM Global Business Services, “The combination of IBM’s technological know-how and the msg life policy administration system will allow for faster implementations, increased flexibility as well as reduced risk and operational costs of our clients.”
About msg life
As part of the independent, internationally active msg Group, msg life ag and its subsidiaries are among the leading software and consulting companies for the European insurance sector. The services of msg life range from the development and implementation of standard software and the provision of consultancy services to the handling of full IT operations (cloud solutions). The msg life Group has its head office in Leinfelden-Echterdingen and offices in Munich, Hamburg and Cologne, plus subsidiaries in the Netherlands, Austria, Switzerland, Slovakia, Slovenia, Portugal and the USA. It currently employs a workforce of nearly 1,200.
About IBM: www.ibm.com
About IBM Services: https://www.ibm.com/de-de/services
Contacts
msg life ag
Frank Fahrner
Corporate Communications
E-mail: frank.fahrner@msg-life.com
Internet: www.msg-life.com
IBM Deutschland GmbH
Beate Werlin
Corporate Communications IBM DACH
E-mail: beate.werlin@de.ibm.com
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
Forum for a self-reliant and self-determined Europe - the "Sovereign Europe Forum"23.12.2025 08:40:47 CET | Press release
Entrepreneurs, top managers and leaders from United Europe e.V. and European Forum Alpbach (EFA) are founding the Sovereign Europe Forum i.G.
Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:12:30 CET | Press release
youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

